Prospective Randomized Clinical Trial
Prospective Randomized Controlled Clinical Trial · Also known as: Prospective RCT, randomized controlled trial, RCT, controlled clinical trial
A prospective randomized clinical trial (RCT) is an experimental study in which participants are assigned to intervention or control groups by chance before any outcomes are observed, then followed forward in time. Random allocation eliminates systematic selection bias, making this design the gold standard for establishing causal efficacy of treatments in medicine and clinical research.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use a prospective RCT when you need causal evidence that an intervention (drug, device, procedure, behavioral program) changes an outcome, and when random assignment is ethically and practically feasible. It is the required design for regulatory submissions to bodies such as the FDA or EMA for new therapeutics. Do not use an RCT when random assignment is unethical (e.g., known harmful exposure), when the outcome is too rare to power adequately, when long latency makes prospective follow-up impractical, or when the research question concerns etiology or prevalence rather than causal efficacy — in those situations, observational or register-based designs are more appropriate.
Strengths & limitations
- Random allocation eliminates unmeasured confounding, providing the strongest available evidence of causal efficacy.
- Pre-registration and protocol publication reduce reporting bias and selective outcome switching.
- Prospective data collection allows standardized, high-quality measurement of exposures, confounders, and outcomes from the outset.
- CONSORT reporting guidelines ensure transparent, reproducible results that can be incorporated into meta-analyses.
- Blinding (where feasible) protects against performance and detection bias.
- Randomization is unethical or impractical for many research questions, limiting applicability to interventions that can be experimentally administered.
- Strict eligibility criteria improve internal validity but may reduce external validity — trial populations often differ from routine clinical practice.
- Prospective follow-up makes RCTs time-consuming and expensive, particularly for outcomes with long latency.
- Intention-to-treat analysis preserves the randomization benefit but may underestimate the biological effect of full adherence to the intervention.
Frequently asked
What is the difference between a prospective RCT and a retrospective RCT?
A prospective RCT randomizes participants at enrollment and then collects outcome data going forward in time — this is the standard design. A so-called retrospective RCT is a contradiction in terms; retrospective studies use existing data collected in the past and cannot randomize participants. Items labeled 'retrospective RCT' in some databases typically refer to secondary analyses of prospectively collected RCT data, not a distinct design.
What is allocation concealment and why is it distinct from blinding?
Allocation concealment prevents anyone involved in enrolling or treating participants from knowing the next assignment before a participant is entered into the trial. Blinding prevents participants and/or investigators from knowing the assignment after enrollment. Both are necessary: without concealment, selection bias can enter during recruitment; without blinding, performance and detection bias can enter during treatment and outcome assessment.
When should I use intention-to-treat versus per-protocol analysis?
Intention-to-treat (ITT) analysis includes all randomized participants in the group to which they were assigned, regardless of adherence, and is the primary analysis protecting the causal interpretation from confounding by adherence. Per-protocol analysis restricts to participants who adhered to the protocol and is subject to selection bias but may better approximate the biological effect of the treatment when adherence is high. Both should typically be reported.
How do I determine the required sample size?
A sample size calculation requires four inputs: the expected outcome rate or mean in the control group, the minimum clinically important difference you want to detect (effect size), the desired statistical power (commonly 80% or 90%), and the significance level (commonly alpha = 0.05 two-sided). Standard formulas or software (e.g., G*Power, R's pwr package) produce the required n per arm. Allow for anticipated dropout by inflating the calculated n.
Is trial registration mandatory?
Prospective registration of the protocol in a public registry (ClinicalTrials.gov, WHO ICTRP, or equivalent) before first participant enrollment is required by the Declaration of Helsinki, by most major journals as a condition of publication, and by most regulatory agencies. Registration timestamps the primary outcome and analysis plan, preventing outcome switching and publication bias.
Sources
- Medical Research Council (1948). Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. British Medical Journal, 2(4582), 769–782. link ↗
- Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332. DOI: 10.1136/bmj.c332 ↗
How to cite this page
ScholarGate. (2026, June 3). Prospective Randomized Controlled Clinical Trial. ScholarGate. https://scholargate.app/en/epidemiology/prospective-randomized-clinical-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Randomized Clinical TrialEpidemiology↔ compare
- Cohort StudyEpidemiology↔ compare
- Phase III clinical trialEpidemiology↔ compare
- Pragmatic randomized clinical trialEpidemiology↔ compare
- Randomized clinical trialEpidemiology↔ compare